NBIX RSI Chart
Last 7 days
-4.3%
Last 30 days
-4.4%
Last 90 days
-3.0%
Trailing 12 Months
27.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 1.6B | 1.7B | 1.8B | 1.9B |
2022 | 1.2B | 1.3B | 1.4B | 1.5B |
2021 | 1.0B | 1.0B | 1.1B | 1.1B |
2020 | 886.8M | 1.0B | 1.0B | 1.0B |
2019 | 518.6M | 605.1M | 675.5M | 788.1M |
2018 | 232.7M | 323.3M | 414.3M | 451.2M |
2017 | 0 | 6.3M | 67.1M | 161.6M |
2016 | 15.0M | 15.0M | 15.0M | 15.0M |
2015 | 22.0M | 21.2M | 20.5M | 19.8M |
2013 | 40.6M | 28.0M | 15.5M | 2.9M |
2012 | 76.2M | 74.6M | 42.3M | 53.1M |
2011 | 45.3M | 52.8M | 80.0M | 77.4M |
2010 | 0 | 13.1M | 23.3M | 33.5M |
2009 | 0 | 0 | 0 | 3.0M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | delaet ingrid | sold | -37,345 | 137 | -272 | chief regulatory officer |
Apr 01, 2024 | delaet ingrid | acquired | 21,493 | 79.02 | 272 | chief regulatory officer |
Mar 21, 2024 | delaet ingrid | acquired | 517,600 | 103 | 5,000 | chief regulatory officer |
Mar 21, 2024 | delaet ingrid | sold | -725,320 | 145 | -5,000 | chief regulatory officer |
Mar 14, 2024 | morrow george j | sold | -5,576,710 | 139 | -40,000 | - |
Mar 14, 2024 | morrow george j | acquired | 795,800 | 39.79 | 20,000 | - |
Mar 14, 2024 | benevich eric | acquired | 6,067,630 | 80.9017 | 75,000 | chief commercial officer |
Mar 14, 2024 | benevich eric | sold | -10,453,400 | 139 | -75,000 | chief commercial officer |
Mar 13, 2024 | delaet ingrid | sold | -420,419 | 140 | -3,000 | chief regulatory officer |
Mar 13, 2024 | pops richard f | acquired | 992,032 | 42.76 | 23,200 | - |
Which funds bought or sold NBIX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 15, 2024 | EXCHANGE TRADED CONCEPTS, LLC | reduced | -20.51 | -159,564 | 790,557 | 0.02% |
Apr 15, 2024 | THOMPSON INVESTMENT MANAGEMENT, INC. | reduced | -0.97 | 37,088 | 1,051,640 | 0.16% |
Apr 15, 2024 | Sunbelt Securities, Inc. | reduced | -10.15 | -2,549 | 40,273 | -% |
Apr 15, 2024 | Pallas Capital Advisors LLC | new | - | 338,042 | 338,042 | 0.01% |
Apr 15, 2024 | Portman Square Capital LLP | unchanged | - | 10,207 | 228,533 | 0.01% |
Apr 15, 2024 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | added | 48.53 | 233,451 | 654,292 | -% |
Apr 15, 2024 | NorthCrest Asset Manangement, LLC | reduced | -5.01 | -4,030 | 706,288 | 0.02% |
Apr 15, 2024 | Concurrent Investment Advisors, LLC | new | - | 331,904 | 331,904 | 0.02% |
Apr 12, 2024 | FCF Advisors LLC | sold off | -100 | -1,157,250 | - | -% |
Apr 12, 2024 | WASHINGTON CAPITAL MANAGEMENT, INC | reduced | -15.79 | -74,180 | 551,680 | 0.45% |
Unveiling Neurocrine Biosciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Neurocrine Biosciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 348.0B | 85.2B | 9.9 | 4.09 | ||||
MRK | 316.7B | 60.1B | 867.76 | 5.27 | ||||
PFE | 145.1B | 46.5B | -104.48 | 3.12 | ||||
AMGN | 142.4B | 28.2B | 21.2 | 5.05 | ||||
GILD | 83.9B | 27.1B | 14.81 | 3.09 | ||||
TEVA | 14.7B | 15.8B | -25.47 | 0.93 | ||||
MID-CAP | ||||||||
PRGO | 4.1B | 4.7B | -319.58 | 0.87 | ||||
ALKS | 4.0B | 1.7B | 11.18 | 2.39 | ||||
BHC | 3.2B | 8.8B | -5.39 | 0.36 | ||||
AMPH | 2.0B | 644.4M | 14.31 | 3.05 | ||||
SMALL-CAP | ||||||||
TLRY | 1.4B | 743.2M | -4.05 | 1.92 | ||||
TXMD | 22.1M | 1.3M | -2.15 | 0.38 | ||||
ACRX | 17.3M | - | -0.94 | 0.22 | ||||
AGRX | 1.2M | 19.6M | -0.08 | 0.06 | ||||
ACOR | 496.8K | 117.6M | 0 | 0 |
Neurocrine Biosciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 3.3% | 515 | 499 | 453 | 420 | 412 | 388 | 378 | 311 | 312 | 296 | 289 | 237 | 248 | 259 | 302 | 237 | 244 | 222 | 184 | 138 | 131 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00 | 2.00 | 2.00 | - | 1.00 | - |
Costs and Expenses | 2.0% | 365 | 358 | 379 | 535 | 309 | 300 | 324 | 308 | 348 | 252 | 226 | 205 | 176 | 303 | 226 | 178 | - | 132 | 149 | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | 326 | - | - | - | 176 | 303 | 226 | 178 | 195 | 132 | 149 | 239 | 110 |
S&GA Expenses | 7.2% | 219 | 204 | 222 | 243 | 183 | 186 | 183 | 201 | 157 | 155 | 143 | 129 | 107 | 113 | 97.00 | 118 | 101 | 85.00 | 81.00 | 88.00 | 69.00 |
R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 73.00 | - | - | - | 58.00 | - | - | 62.00 | 38.00 | 39.00 |
EBITDA Margin | 22.7% | 0.19* | 0.15* | 0.15* | 0.07* | 0.16* | 0.08* | 0.04* | 0.11* | 0.12* | 0.18* | 0.10* | 0.13* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 3.00 | 7.00 | 7.00 | 6.00 | 6.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 |
Income Taxes | 55.4% | 51.00 | 33.00 | 26.00 | -26.70 | 29.00 | 29.00 | -6.40 | 8.00 | -6.50 | 8.00 | 15.00 | -4.90 | -306 | 1.00 | 4.00 | 2.00 | 5.00 | 5.00 | 1.00 | -0.50 | - |
Earnings Before Taxes | 71.5% | 198 | 116 | 122 | -103 | 118 | 98.00 | -23.30 | 21.00 | -13.80 | 31.00 | 58.00 | 27.00 | 42.00 | -57.10 | 83.00 | 39.00 | 39.00 | 58.00 | 52.00 | -102 | 19.00 |
EBT Margin | 24.7% | 0.18* | 0.14* | 0.14* | 0.06* | 0.14* | 0.06* | 0.01* | 0.08* | 0.09* | 0.15* | 0.07* | 0.09* | - | - | - | - | - | - | - | - | - |
Net Income | 77.7% | 148 | 83.00 | 96.00 | -76.60 | 89.00 | 69.00 | -16.90 | 14.00 | -7.30 | 23.00 | 42.00 | 32.00 | 348 | -57.60 | 80.00 | 37.00 | 34.00 | 54.00 | 51.00 | -102 | 18.00 |
Net Income Margin | 23.6% | 0.13* | 0.11* | 0.11* | 0.04* | 0.10* | 0.04* | 0.01* | 0.06* | 0.08* | 0.42* | 0.35* | 0.38* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -42.2% | 118 | 204 | 173 | -133 | 141 | 101 | 129 | -48.10 | -4.70 | 56.00 | 99.00 | 83.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 14.2% | 3,251 | 2,848 | 2,613 | 2,360 | 2,369 | 2,143 | 2,006 | 2,145 | 2,073 | 2,017 | 1,956 | 1,846 | 1,735 | 1,503 | 1,516 | 1,362 | 1,306 | 1,180 | 1,067 | 958 | 993 |
Current Assets | -2.6% | 1,607 | 1,650 | 1,497 | 1,433 | 1,454 | 1,206 | 1,019 | 1,018 | 973 | 1,006 | 1,110 | 1,085 | 1,016 | 1,157 | 1,146 | 968 | 831 | 819 | 749 | 633 | 738 |
Cash Equivalents | -14.5% | 251 | 294 | 160 | 104 | 263 | 212 | 163 | 270 | 344 | 311 | 368 | 353 | 190 | 425 | 415 | 187 | 116 | 172 | 147 | 78.00 | 147 |
Inventory | 33.0% | 38.00 | 29.00 | 32.00 | 33.00 | 35.00 | 37.00 | 29.00 | 29.00 | 31.00 | 26.00 | 28.00 | 30.00 | 28.00 | 21.00 | 22.00 | 21.00 | 17.00 | 11.00 | 12.00 | 13.00 | 11.00 |
Net PPE | 2.9% | 71.00 | 69.00 | 66.00 | 63.00 | 59.00 | 61.00 | 67.00 | 64.00 | 59.00 | 51.00 | 50.00 | 45.00 | 45.00 | 43.00 | 45.00 | 42.00 | 42.00 | 40.00 | 40.00 | 37.00 | 34.00 |
Liabilities | 20.5% | 1,019 | 846 | 760 | 675 | 661 | 599 | 582 | 753 | 699 | 671 | 677 | 641 | 609 | 698 | 684 | 662 | 669 | 605 | 583 | 548 | 512 |
Current Liabilities | -5.3% | 655 | 692 | 583 | 374 | 538 | 485 | 286 | 254 | 246 | 226 | 213 | 190 | 187 | 611 | 573 | 140 | 565 | 116 | 101 | 72.00 | 88.00 |
Long Term Debt | - | - | - | - | 170 | - | - | 169 | 378 | 335 | 331 | 326 | 322 | 318 | - | - | 414 | - | 404 | 398 | 393 | 388 |
LT Debt, Current | 0.1% | 170 | 170 | 170 | - | 169 | 169 | - | - | - | - | - | - | - | 425 | 420 | - | 409 | - | - | - | - |
LT Debt, Non Current | - | - | - | - | 170 | - | - | 169 | 378 | 335 | 331 | 326 | 322 | 318 | - | - | 414 | - | 404 | 398 | 393 | 388 |
Shareholder's Equity | 11.5% | 2,232 | 2,002 | 1,853 | 1,685 | 1,708 | 1,545 | 1,423 | 1,391 | 1,374 | 1,346 | 1,279 | 1,206 | 1,126 | 804 | 831 | 700 | 637 | 575 | 484 | 409 | 481 |
Retained Earnings | 48.5% | -157 | -304 | -387 | -483 | -406 | -495 | -564 | -547 | -635 | -628 | -651 | -693 | -725 | -1,073 | -1,015 | -1,095 | -1,132 | -1,166 | -1,220 | -1,271 | -1,177 |
Additional Paid-In Capital | 3.2% | 2,382 | 2,309 | 2,242 | 2,171 | 2,122 | 2,054 | 2,000 | 1,948 | 2,011 | 1,974 | 1,929 | 1,898 | 1,850 | 1,874 | 1,842 | 1,797 | 1,768 | 1,740 | 1,703 | 1,681 | 1,660 |
Shares Outstanding | 0.5% | 99.00 | 98.00 | 98.00 | 98.00 | 97.00 | 96.00 | 95.00 | 95.00 | 95.00 | 95.00 | 94.00 | 94.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 7,900 | - | - | - | 8,097 | - | - | - | 9,105 | - | - | - | 11,232 | - | - | - | 5,753 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -41.7% | 123,500 | 212,000 | 179,600 | -125,200 | 143,000 | 98,800 | 138,100 | -40,500 | 4,200 | 61,800 | 103,200 | 87,300 | 94,500 | -20,400 | 118,900 | 35,500 | 97,500 | 97,800 | 64,200 | -112,500 | 50,490 |
Share Based Compensation | -20.3% | 38,100 | 47,800 | 68,500 | 39,900 | 43,500 | 43,100 | 49,500 | 37,000 | 35,600 | 37,100 | 28,600 | 32,900 | 21,000 | 26,700 | 29,500 | 22,800 | 21,300 | 20,300 | 17,900 | 15,800 | 13,300 |
Cashflow From Investing | -107.4% | -201,800 | -97,300 | -125,900 | -42,100 | -115,600 | -61,300 | 31,400 | -31,600 | 23,700 | -126,200 | -90,800 | 63,100 | -147,700 | 25,200 | 93,400 | 33,200 | -166,200 | -85,600 | -300 | 41,000 | -106,241 |
Cashflow From Financing | 88.3% | 35,400 | 18,800 | 2,900 | 8,200 | 24,600 | 11,400 | -276,400 | 6,100 | 1,800 | 7,500 | 3,000 | 15,100 | -185,000 | 5,400 | 15,800 | 6,000 | 12,400 | 13,100 | 4,300 | 2,600 | 1,752 |
Consolidated Statements Income and Comprehensive Income - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Revenues | $ 1,887.1 | $ 1,488.7 | $ 1,133.5 |
Operating expenses: | |||
Cost of revenues | 39.7 | 23.2 | 14.3 |
Research and development | 565.0 | 463.8 | 328.1 |
Acquired in-process research and development | 143.9 | 0.0 | 105.3 |
Selling, general and administrative | 887.6 | 752.7 | 583.3 |
Total operating expenses | 1,636.2 | 1,239.7 | 1,031.0 |
Operating income | 250.9 | 249.0 | 102.5 |
Other income (expense): | |||
Interest expense | (4.6) | (7.1) | (25.8) |
Unrealized gain on equity securities | 28.4 | 30.8 | 20.9 |
Loss on extinguishment of convertible senior notes | 0.0 | (70.0) | 0.0 |
Investment income and other, net | 57.4 | 11.2 | 3.8 |
Total other income (expense), net | 81.2 | (35.1) | (1.1) |
Income before provision for income taxes | 332.1 | 213.9 | 101.4 |
Provision for income taxes | 82.4 | 59.4 | 11.8 |
Net income | 249.7 | 154.5 | 89.6 |
Foreign currency translation adjustments, net of tax | 2.4 | 2.9 | 0.0 |
Unrealized gain (loss) on debt securities available-for-sale, net of tax | 12.5 | (9.1) | (3.5) |
Comprehensive income | $ 264.6 | $ 148.3 | $ 86.1 |
Earnings per share, basic (in USD per share) | $ 2.56 | $ 1.61 | $ 0.95 |
Earnings per share, diluted (in USD per share) | $ 2.47 | $ 1.56 | $ 0.92 |
Weighted average common shares outstanding, basic (in shares) | 97.7 | 95.8 | 94.6 |
Weighted average common shares outstanding, diluted (in shares) | 101.0 | 98.9 | 97.9 |
Net product sales | |||
Revenues: | |||
Revenues | $ 1,860.6 | $ 1,440.9 | $ 1,090.1 |
Collaboration revenue | |||
Revenues: | |||
Revenues | $ 26.5 | $ 47.8 | $ 43.4 |
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 251.1 | $ 262.9 |
Debt securities available-for-sale | 780.5 | 726.4 |
Accounts receivable, net | 439.3 | 350.0 |
Inventory, net | 38.3 | 35.1 |
Other current assets | 97.8 | 79.1 |
Total current assets | 1,607.0 | 1,453.5 |
Deferred tax assets | 362.6 | 305.9 |
Debt securities available-for-sale | 687.5 | 299.4 |
Right-of-use assets | 276.5 | 87.0 |
Equity securities | 161.9 | 102.1 |
Property and equipment, net | 70.8 | 58.6 |
Intangible assets, net | 35.5 | 37.2 |
Other assets | 49.6 | 25.0 |
Total assets | 3,251.4 | 2,368.7 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 448.8 | 347.6 |
Convertible senior notes | 170.1 | 169.4 |
Other current liabilities | 35.9 | 20.7 |
Total current liabilities | 654.8 | 537.7 |
Noncurrent operating lease liabilities | 258.3 | 93.5 |
Other long-term liabilities | 106.3 | 29.7 |
Total liabilities | 1,019.4 | 660.9 |
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding | 0.0 | 0.0 |
Common stock, $0.001 par value; 220.0 shares authorized; 98.7 and 96.5 shares issued and outstanding, respectively | 0.1 | 0.1 |
Additional paid-in capital | 2,382.0 | 2,122.4 |
Accumulated other comprehensive income (loss) | 7.0 | (7.9) |
Accumulated deficit | (157.1) | (406.8) |
Total stockholders’ equity | 2,232.0 | 1,707.8 |
Total liabilities and stockholders’ equity | $ 3,251.4 | $ 2,368.7 |
Dr. Kevin C. Gorman Ph.D. | |
neurocrine.com | |
Pharmaceuticals | |
1350 |